Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis

[1]  A. Sayıner,et al.  Hepatitis A, B and C seropositivity among first-year healthcare students in western Turkey: a seroprevalence study , 2020, BMC Infectious Diseases.

[2]  S. Bolukçu,et al.  Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents , 2020, European journal of gastroenterology & hepatology.

[3]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[4]  M. Baymakova,et al.  Trends in the Acute Hepatitis B and Acute Hepatitis C in Bulgaria , 2019, Folia medica.

[5]  K. Minden,et al.  Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood , 2019, Arthritis care & research.

[6]  F. Eser,et al.  High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study , 2019, Human vaccines & immunotherapeutics.

[7]  T. Avčin,et al.  Vaccination coverage in children with rheumatic diseases. , 2019, Clinical and Experimental Rheumatology.

[8]  S. Kamphuis,et al.  Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries , 2018, Arthritis Research & Therapy.

[9]  Y. Camcıoğlu,et al.  The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study , 2018, Clinical Rheumatology.

[10]  A. Atilla,et al.  Where we are in the fight against Hepatitis B Infection; Trends in Hepatitis B virus seroprevalence in Black Sea Region of Turkey , 2018, Nigerian journal of clinical practice.

[11]  H. Ozkan.  Epidemiology of Chronic Hepatitis B in Turkey. , 2018 .

[12]  J. Treat,et al.  Decreased Hepatitis B vaccine response in pediatric patients with atopic dermatitis, psoriasis, and morphea. , 2017, Vaccine.

[13]  U. Heininger,et al.  Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression , 2016, Pediatric Rheumatology.

[14]  Y. Kawano,et al.  The safety and effectiveness of HBV vaccination in patients with juvenile idiopathic arthritis controlled by treatment , 2016, Modern rheumatology.

[15]  U. Akarca,et al.  Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  C. Mengoli,et al.  Immune response to Hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis , 2015, Human vaccines & immunotherapeutics.

[17]  S. Unal,et al.  Missed opportunities for Hepatitis B vaccination among diabetic patients , 2015, Human vaccines & immunotherapeutics.

[18]  G. Tosone,et al.  Prevention of hepatitis B virus infection: from the past to the future , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[19]  G. Karatekin,et al.  Hepatitis B seroprevalence in children and women and the impact of the hepatitis B vaccination program in the Black Sea Region of Turkey. , 2013, Journal of infection in developing countries.

[20]  E. Bonfá,et al.  Vaccinations in juvenile chronic inflammatory diseases: an update , 2013, Nature Reviews Rheumatology.

[21]  A. Soldatou,et al.  Markedly decreased antibody titers against hepatitis B in previously immunised children presenting with juvenile idiopathic arthritis. , 2013, Clinical and experimental rheumatology.

[22]  J. Baddley,et al.  Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. , 2013, Arthritis and rheumatism.

[23]  H. Yikilkan,et al.  Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children , 2012, European Journal of Pediatrics.

[24]  R. Ouellet-Hellstrom,et al.  Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. , 2012, Arthritis and rheumatism.

[25]  N. Wulffraat,et al.  Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study , 2011, Annals of the rheumatic diseases.

[26]  S. Badur,et al.  [Evaluation of serological status of children following hepatitis B vaccination during infancy]. , 2012, Mikrobiyoloji bulteni.

[27]  M. Beresford,et al.  Juvenile Idiopathic Arthritis , 2011, Paediatric drugs.

[28]  M. Carroll.  The impact of biologic response modifiers on hepatitis B virus infection , 2011, Expert opinion on biological therapy.

[29]  Alberto Martini,et al.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[30]  C. Saban,et al.  Trends in Hepatitis B and Hepatitis C Virus among Blood Donors over 16 Years in Turkey , 2006, European Journal of Epidemiology.

[31]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.

[32]  G. Kanra,et al.  Hepatitis B and measles seroprevalence among Turkish children. , 2005, The Turkish journal of pediatrics.

[33]  S. Pol.  [Epidemiology and natural history of hepatitis B]. , 2005, La Revue du praticien.

[34]  B. McMahon,et al.  Epidemiology and Natural History of Hepatitis B , 2005, Seminars in liver disease.

[35]  H. Çam,et al.  Hepatitis B vaccination in children with juvenile idiopathic arthritis , 2004, Annals of the rheumatic diseases.

[36]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[37]  T. Coates,et al.  Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. , 2001, Clinical therapeutics.